Based on discoveries made in the lab of Massachusetts Institute of Technology's Michael Birnbaum, Ph.D., and leveraging pioneering research from leading scientists at the French National Centre for Scientific Research (CNRS), Kelonia's in vivo gene delivery technology enables a few potent lentiviral vector-like particles armed with an adjustable targeting system to precisely, efficiently, and safely deliver payloads exactly where needed to treat a broad range of diseases. The company's early applications combine oncology-targeted therapeutics, such as CAR and T cell receptor molecules, with Kelonia's precision in vivo targeting technology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/29/22 | $50,000,000 | Series A |
Alta Partners Horizons Ventures Venrock | undisclosed |
